EGFR Amplification clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
open to eligible people ages 18 years and up
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
at UCLA UCSD
Our lead scientists for EGFR Amplification research studies include Deborah Wong.
Last updated: